Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 EPS, expectations were $1.85. Operator: Thank you for standing by. Welcome to ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for the treatment of patients with chronic cough in ...

An AstraZeneca Plc and Daiichi Sankyo Co. drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...

(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK ... Monday's Regular trading at $70.08 up $1.02 or 1.48%. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are ...

GlobalData senior analyst Ophelia Chan said: “The promising results from the company’s 12-week Phase II trial of MET-097i are likely to draw significant attention, especially as MET-097i has a longer ...

Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our ...

Kennedy Jr. and Marty Makary signaling a potential shakeup in operations. Three former senior FDA officials, opining for STAT, emphasized the importance of preserving the agency’s defining ...